Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 9/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12470951 | 0.91 | DRD2 (0.45) | CA1CA2CA9LPLLIPG | |
| SCHEMBL595500 | 0.88 | LPL (0.38) | KDM4EMAPTGAAALDH1A1LMNA | |
| SCHEMBL31222957 | 0.88 | LPL (0.38) | KDM4EMAPTGAAALDH1A1LMNA | |
| SCHEMBL12077902 | 0.81 | PARP11 (0.44) | LPLLIPG | |
| SCHEMBL29964464 | 0.81 | PARP11 (0.44) | LPLLIPG | |
| SCHEMBL30320628 | 0.80 | MAPT (0.46) | MAPTCA1CA2CA9LPL | |
| SCHEMBL28383719 | 0.80 | MAPT (0.46) | MAPTCA1CA2CA9LPL | |
| SCHEMBL24820904 | 0.79 | LPL (0.40) | CA12CA1CA2CA9LPL | |
| SCHEMBL12503577 | 0.78 | BACE1 (0.38) | LPLLIPGDRD2 | |
| SCHEMBL4158988 | 0.78 | LPL (0.44) | CA12CA1CA2CA9LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024083111-A1 | NOVEL HETEROCYCLIC COMPOUNDS | 首药控股(北京)股份有限公司 | 2024-04-25 | — | — | WO | disclosed |
| EP-4326715-A1 | TRIAZOLONES, TETRAZOLONES, AND IMIDAZOLONES, OR THEIR SALTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2024-02-28 | — | — | EP | disclosed |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-10-10 | — | — | US | disclosed |
| EP-3768675-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2021-01-27 | — | — | EP | disclosed |
| CN-111886233-A | Novel triazolone derivative or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2020-11-03 | — | — | CN | disclosed |
| US-20200239465-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| EP-3686199-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020121263-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020121261-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-06-18 | — | — | WO | disclosed |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2020-04-30 | — | — | US | disclosed |
| EP-3611174-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | Medshine Discovery Inc. (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-20190322655-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-10-24 | — | — | US | disclosed |
| WO-2019180646-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322655-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SLC10A1, VAPB, VAT1 | KDM4E 4164/4885MAPT 1844/4885GAA 445/4885 |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, LIPC | KDM4E 3949/4885MAPT 1706/4885GAA 337/4885 |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | SSB, IDO1, IDO2 | KDM4E 960/4885MAPT 3453/4885GAA 2741/4885 |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | KDM4E 843/4885MAPT 3092/4885GAA 2363/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | KDM4E 843/4885MAPT 3092/4885GAA 2363/4885 |
| US-20200239465-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | ADORA2A, ADORA2B, ADORA1 | KDM4E 3289/4885MAPT 1929/4885GAA 3734/4885 |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | ADORA2A, ADORA1, ADORA3 | KDM4E 3980/4885MAPT 3834/4885GAA 4477/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | KDM4E 843/4885MAPT 3092/4885GAA 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.